SHANGHAI, Jan. 7 /PRNewswire-Asia/ -- Sundia MediTech Company, Ltd., a leading pharmaceutical R&D outsourcing Service Company in China, announced that the company has been officially recognized as a technically-advanced service enterprise in Shanghai. According to the related policy, the company can get tax holidays in the future. This also demonstrates that Sundia's strong service capability and advanced R&D ability, as well as its good track record over the past several years, were well-recognized again by the Chinese government.
"We are pleased and honored to get this authorization, which is in recognition of the efforts of Sundia's talented team and their hard work," commented Dr. Xiaochuan Wang, Chairman and CEO of Sundia Meditech. "This authorization reflects our commitment to all of our customers. In the past 5 years, we have provided an integrated service of high-quality drug discovery and development in a timely and cost-effective manner to our clients. We will continue to provide the same excellent service in the future."
About Sundia MediTech:
Sundia MediTech Company is a leading integrated pharmaceutical contract research organization (CRO) based in Shanghai, China. It was founded in Shanghai in 2004 by a group of U.S. pharmaceutical industry veterans to provide R&D outsourcing services to biotech and pharmaceutical companies worldwide, ranging from chemical services, medicinal chemistry, biological services, new technology platforms, and pharmaceutical development services.
